Comments on Novo Nordisk’s reply letter on access to insulin
On 23 September 2024, we sent open letters to the leading insulin manufacturers, including Novo Nordisk, with our concerns about affordable access to insulin and insulin pen devices for people with diabetes in low- and middle-income countries. Novo Nordisk replied on 11 October 2024 with this letter, which we have marked up with our comments.
